Utility of DNA Flow Cytometric Analysis of Paraffin-Embedded Tissue in the Risk Stratification and Management of “Indefinite for Dysplasia” in Patients with Inflammatory Bowel Disease.

Utility of DNA Flow Cytometric Analysis of Paraffin-Embedded Tissue in the Risk Stratification and Management of “Indefinite for Dysplasia” in Patients with Inflammatory Bowel Disease. J Crohns Colitis. 2018 Nov 13;: Authors: Wen KW, Rabinovitch PS, Wang D, Huang D, Mattis AN, Choi WT Abstract Background and Aims: The clinical significance of “indefinite for dysplasia” (IND) in patients with inflammatory bowel disease remains unclear. Currently, no biomarker can reliably differentiate reactive changes from true dysplasia and/or risk stratify IND. Methods: Fifty-two IND colon biopsies were analyzed by DNA flow cytometry.…

Read More

‘Quality of Care’ Standards in Inflammatory Bowel Disease: A Systematic Review.

‘Quality of Care’ Standards in Inflammatory Bowel Disease: A Systematic Review. J Crohns Colitis. 2018 Nov 13;: Authors: Fiorino G, Allocca M, Chaparro M, Coenen S, Fidalgo C, Younge L, Gisbert JP Abstract Background: Inflammatory bowel disease [IBD] includes chronic, disabling and progressive conditions that need a complex approach and management. Although several attempts have been made to standardize the care of IBD patients, no clear definitions of a global ‘standard of care’ are currently available. Methods: We performed a systematic review of the available literature, searching for all relevant…

Read More

Fragmented Care is Prevalent among Inflammatory Bowel Disease Readmissions and is Associated with Worse Outcomes.

Related Articles Fragmented Care is Prevalent among Inflammatory Bowel Disease Readmissions and is Associated with Worse Outcomes. Am J Gastroenterol. 2018 Nov 12;: Authors: Cohen-Mekelburg S, Rosenblatt R, Gold S, Shen N, Fortune B, Waljee AK, Saini S, Scherl E, Burakoff R, Unruh M Abstract BACKGROUND: Inflammatory bowel disease (IBD) is a complex chronic disease that often requires a multispeciality approach; thus, IBD patients are prone to care fragmentation. We aim to determine the prevalence of fragmentation among hospitalized IBD patients and identify associated predictors and visit-level outcomes. METHODS: The…

Read More

Stopping 5-aminosalicylates in patients with ulcerative colitis starting biologic therapy does not increase the risk of adverse clinical outcomes: analysis of two nationwide population-based cohorts.

Related Articles Stopping 5-aminosalicylates in patients with ulcerative colitis starting biologic therapy does not increase the risk of adverse clinical outcomes: analysis of two nationwide population-based cohorts. Gut. 2018 Nov 12;: Authors: Ungaro RC, Limketkai BN, Jensen CB, Allin KH, Agrawal M, Ullman T, Colombel JF, Jess T Abstract OBJECTIVE: The benefit of continuing 5-aminosalicylate (5-ASA) in patients with ulcerative colitis (UC) who initiate anti-tumour necrosis factor-alpha (anti-TNF) biologics is unknown. We aimed to compare clinical outcomes in patients with UC already on 5-ASA who started anti-TNF and then either…

Read More

Value-Based Health Care in Inflammatory Bowel Disease.

Value-Based Health Care in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 Nov 09;: Authors: Ahmed Z, Sarvepalli S, Garber A, Regueiro M, Rizk MK Abstract Inflammatory bowel disease (IBD) is a chronic inflammatory disease associated with significant resource utilization and health care burden. It is emerging as a global disease affecting an increasing proportion of the population. Along with evolving epidemiological trends, the paradigm of managing IBD has also changed. With a burgeoning repertoire of therapeutic options, improved use of health informatics, and emphasis on health care value, the treatment…

Read More

The profile of human milk metabolome, cytokines and antibodies in inflammatory bowel diseases versus healthy mothers and potential impact on the newborn.

The profile of human milk metabolome, cytokines and antibodies in inflammatory bowel diseases versus healthy mothers and potential impact on the newborn. J Crohns Colitis. 2018 Nov 12;: Authors: Meng X, Dunsmore G, Koleva P, Elloumi Y, Wu RY, Sutton RT, Ambrosio L, Hotte N, Nguyen V, Madsen KL, Dieleman LA, Chen H, Huang V, Elahi S Abstract Background and Aims: For women with inflammatory bowel disease (IBD), it is not very well known how IBD or IBD treatment impacts their breastmilk components. We aimed to investigate whether breastmilk composition…

Read More

Cannabis, cannabinoids and the endocannabinoid system – is there therapeutic potential for inflammatory bowel disease?

Cannabis, cannabinoids and the endocannabinoid system – is there therapeutic potential for inflammatory bowel disease? J Crohns Colitis. 2018 Nov 12;: Authors: Ambrose T, Simmons A Abstract Cannabis sativa and its extracts have been used for centuries both medicinally and recreationally. There is accumulating evidence that exogenous cannabis and related cannabinoids improve symptoms associated with inflammatory bowel disease such as pain, loss of appetite, and diarrhoea. In vivo, exocannabinoids have been demonstrated to improve colitis, mainly in chemical models.Exocannabinoids signal through the endocannabinoid system, an increasingly understood network of endogenous…

Read More

Mucosal adhesion and anti-inflammatory effects of Lactobacillus rhamnosus GG in the human colonic mucosa: A proof-of-concept study.

Mucosal adhesion and anti-inflammatory effects of Lactobacillus rhamnosus GG in the human colonic mucosa: A proof-of-concept study. World J Gastroenterol. 2018 Nov 07;24(41):4652-4662 Authors: Pagnini C, Corleto VD, Martorelli M, Lanini C, D’Ambra G, Di Giulio E, Delle Fave G Abstract AIM: To investigate the adhesion and anti-inflammatory effects of Lactobacillus rhamnosus GG (LGG) in the colonic mucosa of healthy and ulcerative colitis (UC) patients, both in vivo and ex vivo in an organ culture model. METHODS: For the ex vivo experiment, a total of 98 patients (68 UC patients…

Read More

Damage-associated molecular patterns in inflammatory bowel disease: From biomarkers to therapeutic targets.

Damage-associated molecular patterns in inflammatory bowel disease: From biomarkers to therapeutic targets. World J Gastroenterol. 2018 Nov 07;24(41):4622-4634 Authors: Nanini HF, Bernardazzi C, Castro F, de Souza HSP Abstract The chronic inflammatory process underlying inflammatory bowel disease (IBD), comprising Crohn’s disease and ulcerative colitis, derives from the interplay of several components in a genetically susceptible host. These components include environmental elements and gut microbiota a dysbiosis. For decades, immune abnormalities have been investigated as critically important in IBD pathogenesis, and attempts to develop effective therapies have predominantly targeted the immune…

Read More

Secondary Haemophagocytic Syndrome and Overlapping Immune Reconstitution Syndrome: Life-Threatening Complications of Anti-Tnf-α Treatment for Crohn’s Disease.

Related Articles Secondary Haemophagocytic Syndrome and Overlapping Immune Reconstitution Syndrome: Life-Threatening Complications of Anti-Tnf-α Treatment for Crohn’s Disease. Am J Gastroenterol. 2018 Nov 09;: Authors: Sáez-González E, Salavert M, Cerrillo E, Moret I, Iborra M, Nos P, Beltrán B Abstract PMID: 30413818 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/30413818?dopt=Abstract

Read More
<< Go Back